Tag: event-free survival
Pembrolizumab sets new standard in advanced head and neck cancer surgery, trial shows
Editor's Note According to results from a randomized trial, titled KEYNOTE-689, adding pembrolizumab (Keytruda) to surgery and standard adjuvant therapy significantly prolongs event-free survival (EFS) in patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC), MedPage Today April 28 reports. Experts are calling the findings a major…
Free Daily News
- Study: Long working hours alter brain regions tied to emotion, cognition
- Survey: Burnout, rigid schedules push nurses to leave
- UCLA surgeons perform world’s first bladder transplant
- AHA urges HHS to cut regulations that burden hospitals and staff
- Commentary: Overlooking, underfunding perioperative mental health threatens patients
- Study: Fewer men undergo unnecessary prostate cancer surgery amid rise in active surveillance
- OpenAI benchmarking tool tests healthcare LLMs
- Healthgrades recognizes top 15% of hospitals for patient experience in 2025
- Q1 reports show climb in outpatient surgical volume, diverging trends at Surgery Partners, Ardent Health
- Study: SGLT2 inhibitors raise postop euglycemic ketoacidosis risk but lower mortality
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement